ArticleScientific reports2025
Advanced SPR biosensor with optimized gold-TiO2 D-shaped photonic crystal fiber for precise multi-cancer detection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MoSRSC advances · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this paper, we present the design, investigation, and optimization of a surface plasmon resonance (SPR) biosensor using a D-shaped photonic crystal fiber (PCF) with layers of gold and titanium oxide (TiO₂). The TiO₂ layer is applied on top of the gold layer to enhance sensitivity. This biosensor aims to simplify the manufacturing process while achieving optimal performance through effective coupling. We improved the design by thoroughly analyzing and optimizing various structural parameters to enhance performance. Our biosensor demonstrated exceptional diagnostic accuracy when tested on multiple samples, including cancer cells (Basal, MDA-MB-231, Jurkat, PC-12, and HeLa). The biosensor achieved a maximum wavelength sensitivity (WS) of 42,000 nm/RIU, a maximum amplitude sensitivity (AS) of - 1862.72 RIU, and a maximum figure of merit (FOM) of 1393.128 RIU⁻¹ across the wavelength range from visible to near-infrared and within a refractive index (RI) range of 1.3-1.4. The results indicate that this optimized biosensor exhibits reliable and accurate detection capabilities, capable of measuring minute changes in RI with high precision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.